[FIP1L1-PDGFRalpha-positive myeloproliferative disease with hypereosinophilia: clinical characteristics and pathogenetic therapy].
Nemchenko
I S
IS
Khoroshko
N D
ND
Turkina
A G
AG
Sokolova
M A
MA
Kokhno
A V
AV
Semenova
E A
EA
Zakharova
A V
AV
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D004273:DNA, Neoplasm / Q000235:genetics; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy / Q000209:etiology* / Q000235:genetics; D000068877:Imatinib Mesylate; D007621:Karyotyping; D008297:Male; D009196:Myeloproliferative Disorders / Q000150:complications / Q000188:drug therapy / Q000235:genetics*; D015514:Oncogene Proteins, Fusion; D010879:Piperazines / Q000627:therapeutic use; D017354:Point Mutation; D011743:Pyrimidines / Q000627:therapeutic use; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000235:genetics*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D039221:mRNA Cleavage and Polyadenylation Factors / Q000235:genetics*
D000970:Antineoplastic Agents; D001549:Benzamides; D004273:DNA, Neoplasm; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C479819:FIP1L1-PDGFRA fusion protein, human; D020796:Receptor, Platelet-Derived Growth Factor alpha